Alfa Cytology, a biomedical research and development support provider, has announced the integration of its custom radiolabeling for ADCs and targeted radiopharmaceuticals services with its Radiopharmaceutical Physicochemical Characterization CRO services. This enhancement aims to provide biotechnology companies, pharmaceutical firms, and research institutions with more comprehensive support for radiopharmaceutical development, covering both radiolabeling and critical quality attribute assessment.
Radiopharmaceuticals have become a key area in precision medicine, with applications ranging from cancer diagnosis to targeted therapy. Increasingly, research projects rely on radiolabeling technologies for pharmacokinetic studies, biodistribution analysis, and molecular imaging. The rapid development of ADCs, peptide therapeutics, and targeted small molecules has further driven demand for advanced radiopharmaceutical capabilities. However, successful radiolabeling alone is insufficient; key attributes such as radiochemical purity, stability, lipophilicity, and target-binding capability must also be evaluated to ensure product quality.
Alfa Cytology's integrated service portfolio addresses this need by combining radiolabeling and physicochemical characterization into a coordinated workflow. The company's custom radiolabeling service supports radiolabeling of antibodies, ADCs, peptides, small molecules, and other targeted compounds using various radionuclides for diagnostic and therapeutic applications. These services are applicable to pharmacokinetic studies, biodistribution analysis, molecular imaging, and radiopharmaceutical development. Complementing this, the physicochemical characterization CRO services analyze key parameters including radiochemical purity, stability, lipophilicity (LogP/LogD), and immunoreactivity, enabling systematic evaluation of candidate properties.
"The demand for high-quality radiolabeling and physicochemical characterization data continues to grow as radiopharmaceutical development advances," said a spokesperson for Alfa Cytology. "By integrating our technical capabilities, we aim to provide customers with more efficient research support and help advance the development of innovative radiopharmaceuticals and targeted therapies." The company believes that covering key research activities from radiolabeling to quality attribute assessment helps generate reliable data for candidate evaluation, improving development efficiency and reducing uncertainty throughout the research process.
For more information on Alfa Cytology's radiopharmaceutical development services, visit their website or explore their custom radiolabeling and physicochemical characterization service pages.
